person · Reporting owner

Soni Manmeet Singh

Disclosed activity across 6 companies

Tapewire entity: 38041
SEC CIK: 0001569769

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132	Chief Financial Officer	February 28, 2019	March 01, 2019
ARENA PHARMACEUTICALS INCARNA · Entity 94856	Director	June 17, 2020	June 18, 2020
PULSE BIOSCIENCES, INC.PLSE · Entity 1151	Director	June 11, 2026	June 16, 2026
Summit Therapeutics Inc.SMMT · Entity 3477	Director · COO and CFO	June 04, 2026	June 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date February 28, 2019 · Filed March 01, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.00 · Expires 2029-02-27	Direct	20,000	Reported balance After 2019-02-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-02-28 · Grant · Acquired 20,000 · Balance 20,000 F1: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2018. The reporting person also received 10,000 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests F2: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2018. The reporting person also received 10,000 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests

F2: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

ARENA PHARMACEUTICALS INC

Report date June 17, 2020 · Filed June 18, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,902	Reported balance After 2020-06-17 transaction · row 1 1 source row Row 1 · 2020-06-17 · Sale · Disposed 304 · Balance 5,902 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

Filing footnotes · ownership attribution and instrument terms

F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

PULSE BIOSCIENCES, INC.

Report date June 11, 2026 · Filed June 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11	Direct	30,000	Reported balance After 2026-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.

Summit Therapeutics Inc.

Report date June 04, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,123,603	Ending reported balance After 2026-06-04 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-06-04 · Purchase · Acquired 25,000 · Balance 3,098,603 Row 2 · 2026-06-04 · Purchase · Acquired 25,000 · Balance 3,123,603

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARIAD PHARMACEUTICALS INC

Report date February 16, 2017 · Filed February 16, 2017

Section 16 reporting ended · disclosed 2017-02-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-02-16 transaction · row 1 1 source row Row 1 · 2017-02-16 · Disposition to issuer · Disposed 3,273 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2: Represents Shares purchased through the Company's employee stock purchase plan, including 538 Shares on February 14, 2017.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.47	Direct	Reported balance After 2017-02-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-02-16 · Disposition to issuer · Disposed 550,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2017-02-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-02-16 · Disposition to issuer · Disposed 7,937 · Balance 0 F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the "RSU Payment"). Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash.

F2: Represents Shares purchased through the Company's employee stock purchase plan, including 538 Shares on February 14, 2017.

F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.

F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the "RSU Payment"). Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes.

REATA PHARMACEUTICALS INC

Report date September 26, 2023 · Filed September 26, 2023

Section 16 reporting ended · disclosed 2023-09-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Class A common stockSEC Table I · non-derivative	Direct	Reported balance After 2023-09-26 transaction · row 1 1 source row Row 1 · 2023-09-26 · Disposition to issuer · Disposed 62,621 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.29 · Expires 2031-01-04	Direct	Reported balance After 2023-09-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-09-26 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.32 · Expires 2032-01-03	Direct	Reported balance After 2023-09-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-09-26 · Disposition to issuer · Disposed 75,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.15 · Expires 2032-03-16	Direct	Reported balance After 2023-09-26 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-09-26 · Disposition to issuer · Disposed 75,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.71 · Expires 2033-01-03	Direct	Reported balance After 2023-09-26 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-09-26 · Disposition to issuer · Disposed 95,475 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.70 · Expires 2029-08-28	Direct	Reported balance After 2023-09-26 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-09-26 · Disposition to issuer · Disposed 175,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.79 · Expires 2029-08-28	Direct	Reported balance After 2023-09-26 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-09-26 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $207.20 · Expires 2030-01-02	Direct	Reported balance After 2023-09-26 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-09-26 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)

F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 03, 2023 Filed Jan 5, 2023 21:09 UTC	Summit Therapeutics Inc. SMMT · Entity 3477	GrantStock Option (right to buy) · Derivative	35,000	Not disclosed Strike: $5.00	Not disclosed	Disclosure SEC source: 0001569769-23-000004 · wf-form4_167295295731969.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 3, 2023. The shares underlying the option shall vest in four equal annual installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-employee director on each such vesting date. Read SEC document
May 19, 2022 Filed May 24, 2022 00:53 UTC	PULSE BIOSCIENCES, INC. PLSE · Entity 1151	GrantStock Option (right to buy) · Derivative	116,005	$0.00 Strike: $2.14	$0.00	Disclosure SEC source: 0001104659-22-064004 · tm2216672-3_4seq1.xml · derivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,005 Underlying: Common Stock · 116,005 shares Expires 2032-05-19 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on August 19, 2022. Read SEC document
May 19, 2022 Filed May 24, 2022 00:53 UTC	PULSE BIOSCIENCES, INC. PLSE · Entity 1151	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $2.14	$0.00	Disclosure SEC source: 0001104659-22-064004 · tm2216672-3_4seq1.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-19 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on June 19, 2022. Read SEC document
January 03, 2022 Filed Jan 5, 2022 16:07 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	GrantEmployee Stock Option (right to buy) · Derivative	100,000	$0.00 Strike: $27.32	$0.00	Disclosure SEC source: 0001209191-22-001633 · doc4.xml · derivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Class A common stock · 100,000 shares Expires 2032-01-03 F2 · derivative.exercise_date: The options vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date. Read SEC document
January 03, 2022 Filed Jan 5, 2022 16:07 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	GrantClass A common stock	50,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-001633 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,000 F1 · shares: The shares represent Restricted Stock Units, which vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date. Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:03 UTC	Summit Therapeutics Inc. SMMT · Entity 3477	GrantStock Option (right to buy) · Derivative	82,446	$1.13 Strike: $2.82	$93,163.98	Disclosure SEC source: 0001599298-22-000006 · wf-form4_164141659851379.xml · derivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,446 Underlying: Common Stock · 82,446 shares Expires 2032-01-03 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $93,000. F3 · derivative.exercise_date: The option was issued on January 3, 2022. The shares underlying the option are scheduled to vest in four equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:03 UTC	Summit Therapeutics Inc. SMMT · Entity 3477	GrantStock Option (right to buy) · Derivative	25,000	Not disclosed Strike: $2.82	Not disclosed	Disclosure SEC source: 0001599298-22-000006 · wf-form4_164141659851379.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Read SEC document
December 31, 2021 Filed Jan 4, 2022 08:51 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	PurchaseClass A common stock	16,000	$26.22	$419,564.80	Disclosure SEC source: 0001209191-22-000391 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on one day at prices ranging from $25.97 to $26.46. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth in this footnote. Read SEC document
May 20, 2021 Filed May 21, 2021 21:07 UTC	PULSE BIOSCIENCES, INC. PLSE · Entity 1151	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $18.69	$0.00	Disclosure SEC source: 0001209191-21-035010 · doc4.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-20 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document
February 19, 2021 Filed Feb 23, 2021 23:04 UTC	Summit Therapeutics Inc. SMMT · Entity 3477	GrantStock Option (right to buy) · Derivative	25,000	Not disclosed Strike: $7.33	Not disclosed	Disclosure SEC source: 0000921895-21-000545 · form412566sin_02232021.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,273 Underlying: Common Stock · 25,000 shares Expires 2031-02-19 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on February 19, 2021. The shares underlying the option are scheduled to vest in full on December 31, 2021. Read SEC document
January 04, 2021 Filed Jan 6, 2021 16:43 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	GrantEmployee Stock Option (right to buy) · Derivative	24,000	$0.00 Strike: $121.29	$0.00	Disclosure SEC source: 0001209191-21-002143 · doc4.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Class A common stock · 24,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: The options vest in sixteen equal quarterly installments beginning on April 4, 2021, subject to continued service through each vesting date. Read SEC document
August 14, 2020 Filed Aug 14, 2020 15:45 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	PurchaseClass A common stock	1,000	$100.19	$100,190.00	Disclosure SEC source: 0001209191-20-046765 · doc4.xml · nonDerivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document
August 14, 2020 Filed Aug 14, 2020 15:45 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	PurchaseClass A common stock	2,000	$100.22	$200,440.00	Disclosure SEC source: 0001209191-20-046765 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document
June 17, 2020 Filed Jun 18, 2020 17:07 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	SaleCommon Stock	304	$62.74	$19,072.96	Disclosure SEC source: 0001209191-20-037654 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,902 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. Read SEC document
June 15, 2020 Filed Jun 16, 2020 20:54 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	SaleCommon Stock	1,327	$60.12	$79,779.24	Disclosure SEC source: 0001209191-20-037151 · doc4.xml · nonDerivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,206 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person Read SEC document
June 12, 2020 Filed Jun 16, 2020 20:54 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $61.31	$0.00	Disclosure SEC source: 0001209191-20-037151 · doc4.xml · derivative · entry 3 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-12 F3 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 12, 2020, and are exercisable once vested. Read SEC document
June 12, 2020 Filed Jun 16, 2020 20:54 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantCommon Stock	2,446	$0.00	$0.00	Disclosure SEC source: 0001209191-20-037151 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,533 F1 · shares: The amount represents restricted stock units that vest in full on the earliest of June 12, 2021, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units. Read SEC document
May 18, 2020 Filed May 19, 2020 22:25 UTC	PULSE BIOSCIENCES, INC. PLSE · Entity 1151	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $10.66	$0.00	Disclosure SEC source: 0001209191-20-030680 · doc4.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document
January 02, 2020 Filed Jan 6, 2020 15:04 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	GrantEmployee Stock Option (right to buy) · Derivative	25,000	$0.00 Strike: $207.20	$0.00	Disclosure SEC source: 0001209191-20-001636 · doc4.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class B common stock · 25,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: The options vest in sixteen equal quarterly installments beginning on April 2, 2020, subject to continued service through each vesting date. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document
August 28, 2019 Filed Aug 29, 2019 16:20 UTC	REATA PHARMACEUTICALS INC RETA · Entity 12293	GrantEmployee Stock Option (right to buy) · Derivative	250,000	$0.00 Strike: $72.70	$0.00	Disclosure SEC source: 0001209191-19-047700 · doc4.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Class B common stock · 250,000 shares Expires 2029-08-28 F1 · derivative.exercise_date: The option, representing a right to purchase a total of 250,000 shares, becomes exercisable as to 62,500 shares on August 28, 2020, with the remainder to vest in twelve equal quarterly installments thereafter, subject to continued service through each vesting date. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document
June 14, 2019 Filed Jun 17, 2019 18:53 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	SaleCommon Stock	133	$56.51	$7,516.04	Disclosure SEC source: 0001209191-19-037506 · doc4.xml · nonDerivative · entry 3 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,087 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.48 to $56.64, inclusive. Read SEC document
June 14, 2019 Filed Jun 17, 2019 18:53 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	SaleCommon Stock	1,084	$55.82	$60,505.84	Disclosure SEC source: 0001209191-19-037506 · doc4.xml · nonDerivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,220 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.47 to $56.43, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4 to this Form 4. Read SEC document
June 13, 2019 Filed Jun 17, 2019 18:53 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $56.50	$0.00	Disclosure SEC source: 0001209191-19-037506 · doc4.xml · derivative · entry 4 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2026-06-13 F5 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 13, 2019, and are exercisable once vested. Read SEC document
June 13, 2019 Filed Jun 17, 2019 18:53 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantCommon Stock	2,654	$0.00	$0.00	Disclosure SEC source: 0001209191-19-037506 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,304 F1 · shares: The amount represents restricted stock units that vest in full on the earliest of June 13, 2020, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units. Read SEC document
May 16, 2019 Filed May 17, 2019 20:17 UTC	PULSE BIOSCIENCES, INC. PLSE · Entity 1151	GrantStock Option (right to buy) · Derivative	13,814	$0.00 Strike: $13.03	$0.00	Disclosure SEC source: 0001209191-19-030896 · doc4.xml · derivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,814 Underlying: Common Stock · 13,814 shares Expires 2029-05-16 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document
May 16, 2019 Filed May 17, 2019 20:17 UTC	PULSE BIOSCIENCES, INC. PLSE · Entity 1151	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $13.03	$0.00	Disclosure SEC source: 0001209191-19-030896 · doc4.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document
February 28, 2019 Filed Mar 1, 2019 23:10 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $85.00	$0.00	Disclosure SEC source: 0001735276-19-000033 · edgardoc.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-02-27 F1 · shares: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2018. The reporting person also received 10,000 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document
January 07, 2019 Filed Jan 9, 2019 21:15 UTC	PULSE BIOSCIENCES, INC. PLSE · Entity 1151	GrantStock Option (right to buy) · Derivative	4,066	$0.00 Strike: $13.22	$0.00	Disclosure SEC source: 0001209191-19-003039 · doc4.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,066 Underlying: Common Stock · 4,066 shares Expires 2029-01-07 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the date of the Issuer's Annual Meeting to be held in 2019, subject to the Reporting Person's continued service through such vesting date. Read SEC document
December 14, 2018 Filed Dec 17, 2018 16:25 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantStock Option (right to buy) · Derivative	2,500	$0.00 Strike: $41.09	$0.00	Disclosure SEC source: 0001209191-18-062940 · doc4.xml · derivative · entry 4 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2025-12-14 F4 · derivative.exercise_date: The options vest in equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) beginning on the one-month anniversary of the grant date and ending on the one-year anniversary of our most recent annual meeting of stockholders, and are exercisable once vested. Read SEC document
December 14, 2018 Filed Dec 17, 2018 16:25 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantStock Option (right to buy) · Derivative	2,500	$0.00 Strike: $41.09	$0.00	Disclosure SEC source: 0001209191-18-062940 · doc4.xml · derivative · entry 3 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2025-12-14 F3 · derivative.exercise_date: The options vest in 36 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over three years beginning on January 14, 2019, and are exercisable once vested. Read SEC document
December 14, 2018 Filed Dec 17, 2018 16:25 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantCommon Stock	1,825	$0.00	$0.00	Disclosure SEC source: 0001209191-18-062940 · doc4.xml · nonDerivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,825 F2 · shares: The amount represents restricted stock units that vest in full on the earliest of June 13, 2019, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units. Read SEC document
December 14, 2018 Filed Dec 17, 2018 16:25 UTC	ARENA PHARMACEUTICALS INC ARNA · Entity 94856	GrantCommon Stock	1,825	$0.00	$0.00	Disclosure SEC source: 0001209191-18-062940 · doc4.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,825 F1 · shares: The amount represents restricted stock units that vest in three equal installments on the dates of Arena's next three annual meetings of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units. Read SEC document
August 13, 2018 Filed Aug 14, 2018 21:54 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantPerformance Stock Option 2017 (right to buy) · Derivative	25,000	$0.00 Strike: $52.61	$0.00	Disclosure SEC source: 0001735276-18-000048 · edgardoc.xml · derivative · entry 6 Soni Manmeet Singh · CIK 0001569769 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-08 F2 · kind: On May 8, 2017, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. The shares subject to the option will vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the option shares have vested. Read SEC document
July 10, 2018 Filed Aug 14, 2018 21:54 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	OtherCommon Stock	36	$0.00	$0.00	Disclosure SEC source: 0001735276-18-000048 · edgardoc.xml · nonDerivative · entry 5 Soni Manmeet Singh · CIK 0001569769 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 83 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document
May 23, 2018 Filed May 24, 2018 22:38 UTC	PULSE BIOSCIENCES, INC. PLSE · Entity 1151	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $15.27	$0.00	Disclosure SEC source: 0001209191-18-033155 · doc4.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-23 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document
April 16, 2018 Filed Aug 14, 2018 21:54 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	OtherCommon Stock	28	$0.00	$0.00	Disclosure SEC source: 0001735276-18-000048 · edgardoc.xml · nonDerivative · entry 4 Soni Manmeet Singh · CIK 0001569769 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 47 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document
March 01, 2018 Filed Mar 5, 2018 22:49 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	8,938	$0.00 Strike: $119.13	$0.00	Disclosure SEC source: 0001553878-18-000014 · edgardoc.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,938 Underlying: Common Stock · 8,938 shares Expires 2028-02-28 F1 · shares: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2017. The reporting person also received 8,937 options to purchase shares of ALNY common stock that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to the remaining shares ratably at the end of each three-month period thereafter over the following thirty-three (33) months Read SEC document
January 17, 2018 Filed Aug 14, 2018 21:54 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	OtherCommon Stock	6	$0.00	$0.00	Disclosure SEC source: 0001735276-18-000048 · edgardoc.xml · nonDerivative · entry 3 Soni Manmeet Singh · CIK 0001569769 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 19 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document
November 02, 2017 Filed Nov 6, 2017 21:44 UTC	PULSE BIOSCIENCES, INC. PLSE · Entity 1151	GrantStock Option (right to buy) · Derivative	65,000	$0.00 Strike: $23.08	$0.00	Disclosure SEC source: 0001209191-17-059429 · doc4.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-11-02 F1 · derivative.exercise_date: One-third (1/3) of the shares subject to the option will vest on November 2, 2018, and the remaining shares will vest in equal monthly installments thereafter over the following two year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document
October 16, 2017 Filed Aug 14, 2018 21:54 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	OtherCommon Stock	11	$0.00	$0.00	Disclosure SEC source: 0001735276-18-000048 · edgardoc.xml · nonDerivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 13 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document
July 25, 2017 Filed Aug 14, 2018 21:54 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	OtherCommon Stock	2	$0.00	$0.00	Disclosure SEC source: 0001735276-18-000048 · edgardoc.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 2 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:14 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerRestricted Stock Units · Derivative	7,937	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000884731-17-000049 · wf-form4_148727247586013.xml · derivative · entry 3 Soni Manmeet Singh · CIK 0001569769 · EVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,937 shares Expires not disclosed F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the "RSU Payment"). Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the "RSU Payment"). Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:14 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	550,000	$0.00 Strike: $6.47	$0.00	Disclosure SEC source: 0000884731-17-000049 · wf-form4_148727247586013.xml · derivative · entry 2 Soni Manmeet Singh · CIK 0001569769 · EVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 550,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:14 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerCommon Stock	3,273	Not disclosed	Not disclosed	Disclosure SEC source: 0000884731-17-000049 · wf-form4_148727247586013.xml · nonDerivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · EVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2 · price: Represents Shares purchased through the Company's employee stock purchase plan, including 538 Shares on February 14, 2017. Read SEC document
February 06, 2017 Filed Feb 7, 2017 16:58 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	GrantRestricted Stock Units · Derivative	7,937	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000884731-17-000030 · wf-form4_148650471771951.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · EVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,937 Underlying: Common Stock · 7,937 shares Expires not disclosed F1 · derivative.exercise_date: The Restricted Stock Units ("RSUs") vest as to approximately one-third of the shares underlying the RSUs on each anniversary of the grant date; provided, however, that, subject to and effective upon the consummation of the transactions contemplated by that certain Agreement and Plan of Merger between ARIAD, Takeda Pharmaceutical Company Limited, and Kiku Merger Co., Inc., dated January 8, 2017, the RSUs shall be converted into the right to receive a cash amount equal to $24.00 for each share of common stock underlying the RSUs, payable in three annual installments on each anniversary of the grant date, subject to the terms of the award. F2 · derivative.expiration_date: N/A Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.